Profiling the effects of process changes on residual host cell proteins in biotherapeutics by mass spectrometry

Biotechnology Progress

Volumn 29, Issue 4, 2013, Pages 951-957

  Schenauer, Matthew R ^a,b   Flynn, Gregory C ^a   Goetze, Andrew M ^a  

^a AMGEN INC   (United States)

^b NONE   (United States)

Author keywords

Biotherapeutics; Host cell proteins; Mass spectrometry

Indexed keywords

ESCHERICHIA COLI; LIQUID CHROMATOGRAPHY; MASS SPECTROMETRY; PURIFICATION; RISK ASSESSMENT; SAFETY ENGINEERING;

BIOTHERAPEUTICS; ENZYME LINKED IMMUNOSORBENT ASSAY; HOST CELL PROTEIN; IMPURITY PROFILE; LIQUID CHROMATOGRAPHY/MASS SPECTROMETRY; MULTIPLE PROCESS; PROCESS DEVELOPMENT; PURIFICATION PROCESS;

PROTEINS;

ESCHERICHIA COLI;

PROTEIN;

ARTICLE; BIOTECHNOLOGY; BIOTHERAPEUTICS; ENZYME LINKED IMMUNOSORBENT ASSAY; HOST CELL PROTEINS; ISOLATION AND PURIFICATION; LIQUID CHROMATOGRAPHY; MASS SPECTROMETRY;

BIOTHERAPEUTICS; HOST CELL PROTEINS; MASS SPECTROMETRY;

BIOTECHNOLOGY; CHROMATOGRAPHY, LIQUID; ENZYME-LINKED IMMUNOSORBENT ASSAY; MASS SPECTROMETRY; PROTEINS;

EID: 84881613469     PISSN: 87567938     EISSN: 15206033     Source Type: Journal    
DOI: 10.1002/btpr.1748     Document Type: Article

References (20)

1. Wadhwa M, Skog AL, Bird C, Ragnhammar P, Lilljefors M, Gaines-das R, Mellstedt H, Thorpe R. Immunogenicity of granulocyte-macrophage colony-stimulating factor (GM-CSF) products in patients undergoing combination therapy with GM-CSF. Clin Cancer Res. 1999;5:1353-1361.
2. Bierich JR. Treatment by hGH of constitutional delay of growth and adolescence. Acta Paediatr Scand Suppl. 1986;325:71-75.
3. Pavlovic M, Girardin E, Kapetanovic L, Ho K, Trouvin JH. Similar biological medicinal products containing recombinant human growth hormone: European regulation. Horm Res. 2008;69:14-21.
4. Gao SX, Zhang Y, Stansberry-Perkins K, Buko A, Bai S, Nguyen V, Brader ML. Fragmentation of a highly purified monoclonal antibody attributed to residual CHO cell protease activity. Biotechnol Bioeng. 2011;108:977-982.
5. Briggs J, Panfili PR. Quantitation of DNA and protein impurities in biopharmaceuticals. Anal Chem. 1991;63:850-859.
6. ICH. ICH Harmonized Tripartite Guideline. Specifications: Test Procedures and Acceptance Criteria for Biotechnological/Biological Products Q6B; 1999.
7. Champion K, Madden H, Dougherty J, Shacter E. Defining your product profile and maintaining control over it, Part 2. BioProcess Int. 2005;3:52-57.
8. Eaton LC. Host cell contaminant protein assay development for recombinant biopharmaceuticals. J Chromatogr A. 1995;705:105-114.
9. Doneanu CE, Xenopoulos A, Fadgen K, Murphy J, Skilton SJ, Prentice H, Stapels M, Chen W. Analysis of host-cell proteins in biotherapeutic proteins by comprehensive online two-dimensional liquid chromatography/mass spectrometry. MAbs. 2012;4:24-44.
10. Schenauer MR, Flynn GC, Goetze AM. Identification and quantification of host cell protein impurities in biotherapeutics using mass spectrometry. Anal Biochem. 2012;428:150-157.
11. Geromanos SJ, Vissers JP, Silva JC, Dorschel CA, Li GZ, Gorenstein MV, Bateman RH, Langridge JI. The detection, correlation, and comparison of peptide precursor and product ions from data independent LC-MS with data dependant LC-MS/MS. Proteomics. 2009;9:1683-1695.
12. Silva JC, Denny R, Dorschel CA, Gorenstein M, Kass IJ, Li GZ, McKenna T, Nold MJ, Richardson K, Young P, Geromanos S. Quantitative proteomic analysis by accurate mass retention time pairs. Anal Chem. 1 2005;77:2187-2200.
13. Blackburn K, Mbeunkui F, Mitra SK, Mentzel T, Goshe MB. Improving protein and proteome coverage through data-independent multiplexed peptide fragmentation. J Proteome Res. 2010;9:3621-3637.
14. Plumb RS, Johnson KA, Rainville P, Smith BW, Wilson ID, Castro-Perez JM, Nicholson JK. UPLC/MS(E); a new approach for generating molecular fragment information for biomarker structure elucidation. Rapid Commun Mass Spectrom. 2006;20:1989-1994.
15. Shimamoto G, Gegg C, Boone T, Queva C. Peptibodies: a flexible alternative format to antibodies. MAbs. 2012;4:586-591.
16. Champion KM, Nishihara JC, Aldor IS, Moreno GT, Andersen D, Stults KL, Vanderlaan M. Comparison of the Escherichia coli proteomes for recombinant human growth hormone producing and nonproducing fermentations. Proteomics. 2003;3:1365-1373.
17. Bukau B, Horwich AL. The Hsp70 and Hsp60 chaperone machines. Cell. 1998;92:351-366.
18. Wang X, Hunter AK, Mozier NM. Host cell proteins in biologics development: identification, quantitation and risk assessment. Biotechnol Bioeng. 2009;103:446-458.
19. FDA. Pharmaceutical cGMPs for the 21st century: a risk-based approach. Rockville, MD: FDA, September 2004; 2004.
20. Rathore AS, Winkle H. Quality by design for biopharmaceuticals. Nat Biotechnol. 2009;27:26-34.